CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) shares were up 0.8% during trading on Friday after Citigroup raised their price target on the stock from $88.00 to $89.00. Citigroup currently has a buy rating on the stock. CRISPR Therapeutics traded as high as $57.50 and last traded at $56.59. Approximately 332,941 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 1,825,252 shares. The stock had previously closed at $56.16.
CRSP has been the subject of a number of other research reports. Morgan Stanley raised their price objective on CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research note on Monday, February 26th. Wells Fargo & Company lifted their price target on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Royal Bank of Canada upped their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Mizuho boosted their target price on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Finally, Barclays raised their price target on shares of CRISPR Therapeutics from $61.00 to $80.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $76.29.
View Our Latest Analysis on CRISPR Therapeutics
Insider Buying and Selling
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. SeaCrest Wealth Management LLC bought a new stake in CRISPR Therapeutics during the first quarter worth about $229,000. InTrack Investment Management Inc bought a new stake in CRISPR Therapeutics in the 1st quarter worth approximately $522,000. Allspring Global Investments Holdings LLC boosted its stake in CRISPR Therapeutics by 113.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 78,924 shares of the company’s stock worth $5,379,000 after buying an additional 41,903 shares in the last quarter. Mirador Capital Partners LP bought a new position in CRISPR Therapeutics during the first quarter valued at approximately $203,000. Finally, SteelPeak Wealth LLC raised its stake in shares of CRISPR Therapeutics by 129.4% during the first quarter. SteelPeak Wealth LLC now owns 10,253 shares of the company’s stock worth $699,000 after acquiring an additional 5,784 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.
CRISPR Therapeutics Trading Down 0.4 %
The stock has a market capitalization of $4.75 billion, a P/E ratio of -28.87 and a beta of 1.76. The stock’s fifty day moving average price is $73.51 and its two-hundred day moving average price is $63.34.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.95. The business had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. During the same period in the prior year, the firm earned ($1.41) earnings per share. The business’s revenue for the quarter was up 3253.3% on a year-over-year basis. As a group, analysts expect that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Read More
- Five stocks we like better than CRISPR Therapeutics
- The Most Important Warren Buffett Stock for Investors: His Own
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
- How to Calculate Inflation Rate
- Salesforce Stock Analysis: Deep Dive into CRM Market Performance
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.